Mithra Issues First Put Option Notice Under Capital Agreement with LDA Capital

Liege, Belgium, 05 June 2020 – 7:30 CEST – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that following the signature of the capital commitment agreement with LDA Capital Limited announced on April 24, 2020, the Board of Directors approved on May 22, 2020 an increase to the Company’s capital by means of an issuance of new ordinary shares through authorized capital. The first put option notice was issued last Friday, May 29, 2020, according to the terms of the capital commitment agreement.


 

 

Mithra Obtains a Capital Commitment Agreement of EUR 50 Million from Partner LDA Capital

Liege, Belgium, 24 April 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into a capital commitment agreement with LDA Capital Limited, a Los Angeles based global investment group with expertise in cross border transactions in life science sector.

Mithra Releases 2019 Annual Report and Invitation to its Securities holders’ Meeting

Liege, Belgium, 22 April 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the publication of its 2019 Annual Report and the invitation to its Ordinary and Extraordinary General Securities holders.

2019 Annual Report

The Annual Report which outlines Mithra’s achievements in 2019 includes the following information:

  • Overview of Mithra’s R&D pipeline and Letter to Shareholders;
  • Highlights of Mithra’s Strategy and Outlook for 2020;
  • Management Report;
  • Remuneration Report;
  • Financial statements and notes.

The Annual Report is available in English and French and can be read (or downloaded in PDF) on the website investors.mithra.com. In case of interpretation differences, the French version will prevail.

François Fornieri, CEO Mithra Women’s Health, commented:

2019 marked our 20th anniversary and was exceptional in more ways than one. We recorded a strong turnover increase, achieved key milestones in both clinical development and international growth, and a CDMO that successfully moved into commercial production. In 2020, despite this unprecedented situation caused by Covid-19, our teams are determined to do everything possible to meet our ambitious challenges.”

 



 

General Shareholders’ meeting

Mithra is pleased to invite its securities holders to its Ordinary and Extraordinary General Shareholder’s meeting that will be held on Friday May 22 2020 at 2:00 PM (CEST).

The notice for the General Shareholder’s Meeting including a description of the formalities to participate in the Meeting is available on the website investors.mithra.com.

Exceptional organisational arrangements due to Covid-19 have been made

 

Mithra Reports Full Year 2019 Financial Results

  • Record revenue (EUR 96.5 million) and EBITDA (EUR 40.7 million) increased respectively by 47% and 6%, mainly driven by U.S. deal for Estelle®
  • Anticipated future licensing milestones for Estelle® of EUR 322 million (out of a total of EUR 486 million)
  • Net loss significantly reduced to EUR 26.6 million (EUR 89.7 million in June 2019) thanks to successful earnout renegotiation and landmark deal with Mayne Pharma for Estelle®
  • Strengthening of book equity to EUR 163.3 million thanks to earnout renegotiation
  • Continued good cash management with comfortable level of cash at year-end
  • Key milestones achieved for environmental-friendly E4-based portfolio pipeline, with successful launch of Phase III study of Donesta® in menopause and regulatory submission of Estelle® in Europe
  • Valuation of business entity for clinical development projects based on E4 in 2020


Liege, Belgium, 09 March 2020 – 7:30  CET
– Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its financial results for the year ended 31 December 2019, prepared in accordance with IFRS.

Mithra to Host Webcast for Announcement 2019 Financial Results on 9 March 2020

Liege, Belgium, 05 March 2020 – 17:45  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it will host a live webcast on Monday 9 March 2020 at 15:00 CET/ 09:00 EST to announce its 2019 financial and operating results.

Mithra receives positive ruling on Patent Income Deduction

Liege, Belgium, 10 February 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has received a positive ruling from the Belgian tax authorities, enabling Mithra to benefit from the Belgian Patent Income Deduction (PID) 1 on patent related income arising from Mithra’s E4-based products (Estelle®, Donesta®).

Statement from the CEO and the Board of Directors of Mithra following the articles published in the Belgian press

Liege, Belgium, 23 January 2020 – Following publications in the press on Wednesday, 22 January 2020 regarding an alleged insider trading offence attributed to Mr. François Fornieri, CEO of Mithra Pharmaceuticals, Mr. Fornieri vigorously contests any involvement in any such offence and deeply regrets the prejudice caused by this alleged information to Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health.

Mithra Announces 2020 Financial Calendar

Liege, Belgium, 15 January 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company focused on women’s health, today announces its financial calendar for 2020 :

  • 9 March 2020 : 2019 Full Year Results
  • 22 April 2020 : 2019 Annual Report
  • 22 May 2020 : Annual General Shareholders Meeting
  • 24 September 2020 : 2020 Interim report

This calendar and all corporate information on the Company, such as its financial statements, events or corporate presentations, is available on the Company’s website in the Investors’ section (investors.mithra.com).

Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 24 December 2019 – 07:30 CET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 1,444,250 new shares on 20 December 2019, in execution of the principle agreement concluded on 30 September with the former owners of Uteron Pharma relating to the remaining payment obligations that Mithra has under the current earnout agreement.

Mithra Receives EUR 2.9 Million in Non-dilutive Funding

Liege, Belgium, 23 December 2019 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has been granted EUR 2.9 million in non-dilutive funding from the Walloon Region. The grant follows a decision by Mr Willy Borsus, Vice President of the Walloon Government and Minister of Economy, Foreign Trade, Research & Innovation, New Technologies, Agriculture and Urban and Spatial Planning.